Biotechnology
Innovent Announces NMPA Acceptance of a Supplemental New Drug Application for Sintilimab in Combination with Chemotherapy as First-Line Therapy for Esophageal Squamous Cell Carcinoma (ESCC)
SAN FRANCISCO and SUZHOU, China, Sept. 23, 2021 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of cancer, metabolic, autoimmune and other major disea...
2021-09-23 08:00
4441
MedAlliance announces completion of enrollment in Japanese SELUTION SLR™ Study
GENEVA, Sept. 23, 2021 /PRNewswire/ -- MedAlliance, with its Japanese partner MDK Medical, has completed enrollment in the clinical study of its novel Sirolimus Drug Eluting Balloon (DEB), SELUTION SLR™, for the treatment of peripheral arterial disease (PAD). This follows the acceptance of a Clin...
2021-09-23 08:00
3611
INOVIO Receives Regulatory Authorization to Conduct Phase 3 Efficacy Trial of its COVID-19 DNA Vaccine Candidate, INO-4800, in Mexico
News follows recent regulatory authorizations to proceed with the trial in Brazil and the Philippines INOVIO and partner Advaccine are collaborating on the global Phase 3 trial in regions underserved by COVID-19 vaccines; to focus onLatin America, Asia, and Africa PLYMOUTH MEETING, Pa., Sept. 2...
2021-09-22 20:00
6281
LSO Medical Announces CE Approval of Next-Gen LUMESEAL Laser for Treatment of Varicose Vein.
LILLE, France, Sept. 22, 2021 /PRNewswire/ -- LSO MEDICAL SAS, international leader in vascular laser therapies, announced today the CE Approval of its newest generation EVLT SnakeBack® assisted system, the LUMESEAL® laser platform. Designed to enhance ease-of-use and to provide greater precision...
2021-09-22 03:04
2517
Novavax to Participate in Fireside Chat at Devex @ UNGA 76
GAITHERSBURG, Md., Sept. 21, 2021 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing and commercializing next-generation vaccines for serious infectious diseases, today announced thatJohn J. Trizzino, Executive Vice President, Chief Commercial Officer and Chief Busin...
2021-09-21 04:46
8326
RhoVac announces the completion of patient recruitment for the BRaVac clinical phase IIb study of RV001 in prostate cancer
STOCKHOLM, Sept. 21, 2021 /PRNewswire/ -- RhoVac AB ("RhoVac"), a Swedish cancer immunotherapy company, announces today onSep 20th , 2021, that its clinical phase IIb study of lead drug candidate RV001 in prostate cancer, BRaVac, is deemed fully recruited and that no additional patients will be ...
2021-09-21 04:06
1970
Terumo celebrates 100-year anniversary in Asia with an eye to the future
SINGAPORE, Sept. 20, 2021 /PRNewswire/ -- Terumo, a global leader in medical technology, celebrates its centenary inAsia. From humble beginnings as a thermometer manufacturer in 1921, and the first company in 1963 to create disposable syringes inJapan, the company has been providing medical solut...
2021-09-20 10:00
4111
Illumina reaffirms commitment to the National Project of Bio Big Data in Korea
MELBOURNE, Australia, Sept. 20, 2021 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today announced that the National Project of Bio Big Data in Korea has selected Illumina technology for the second pilot project in their effort to work towards establishing a national digital library on health and...
2021-09-20 07:00
6400
Innovent Releases Interim Analysis Results of Sintilimab plus Chemotherapy for the First-Line Treatment of Esophageal Squamous Cell Carcinoma in the Phase 3 ORIENT-15 Study at ESMO Congress 2021
SAN FRANCISCO and SUZHOU, China, Sept. 18, 2021 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of cancer, metabolic, autoimmune and other major dis...
2021-09-18 08:00
8044
Global Cord Blood Corporation to Hold Annual General Meeting in Hong Kong on December 7, 2021
HONG KONG, Sept. 17, 2021 /PRNewswire/ -- Global Cord Blood Corporation (NYSE: CO) ("GCBC" or the "Company"),China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing, and stem cell storage services, today announced that the Company will hold its 20...
2021-09-17 19:00
19207
Zhongchao Inc. Launches Hematology MDT Training Platform to Improve Diagnosis and Treatment
SHANGHAI, Sept. 17, 2021 /PRNewswire/ -- Zhongchao Inc. (NASDAQ: ZCMD) ("Zhongchao" or the "Company"), an internet technology company offering healthcare professionals the online healthcare information, professional training and educational services platform and patients the patient management p...
2021-09-17 18:30
15415
BioVaxys Cancer Vaccine Manufacturing Partner Bio Elpida Reaches Bioproduction Milestone
VANCOUVER, British Columbia, Sept. 17, 2021 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys"), announced today that cancer vaccine manufacturing partner Bio Elpida inLyon, France, has reached major milestones in the development of the bioproduction proce...
2021-09-17 15:00
6291
Innovent Releases Phase 2 Results of Pemigatinib in Chinese Patients with Advanced Cholangiocarcinoma at ESMO Congress 2021
SAN FRANCISCO and SUZHOU, China, Sept. 17, 2021 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent", HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of cancer, metabolic, autoimmune and other major dise...
2021-09-17 08:00
6880
PharmaZell and Novasep enter into exclusive negotiations in new drive to create a technology-driven leader for complex small molecules and ADCs of global scale
RAUBLING, Germany and LYON, France, Sept. 17, 2021 /PRNewswire/ -- PharmaZell, the German producer of highly resilient and specialty APIs, andFrance-based Novasep, a leading CDMO focused on complex small molecules and ADCs have entered into exclusive negotiations to create a leading European plat...
2021-09-17 03:59
3357
Beyond Ventures' first investment, Prenetics, becomes first Hong Kong unicorn to go public
HONG KONG, Sept. 16, 2021 /PRNewswire/ -- Hong Kong-based venture capital firm Beyond Ventures is pleased to support today's announcement by the firm's first investee company, Prenetics, that Prenetics, a global leader in genomic and diagnostic testing is set to merge with Artisan Acquisition Cor...
2021-09-16 15:31
2729
SuperTrans Medical supported by U.S. National Institutes of Health (NIH) in developing its lead antibiotic against urgent threat drug resistant bacteria
SYDNEY, Sept. 16, 2021 /PRNewswire/ -- SuperTrans Medical ("STM"), a biopharmaceutical company developing novel antibiotics that target difficult-to-treat, multi-drug resistant bacterial infections, has announced that the U.S. National Institutes of Health (NIH) will be supporting additional dev...
2021-09-16 08:45
3695
Eleva Reaches Industrial Production Scale and Prepares for Clinical Development of Factor H
FREIBURG, Germany, Sept. 14, 2021 /PRNewswire/ -- Eleva, a manufacturer of superior biologics, is scaling up its production capacity to 2500 l in state-of-the-art single-use reactors. This will produce enough factor H to cover all three clinical phases. Eleva has ordered four more state-of-the-a...
2021-09-14 10:30
2233
RedHill Biopharma Accelerates Ongoing U.S. Phase 2/3 COVID-19 Study of Once-Daily Oral RHB-107 in Non-Hospitalized Patients with South African Approval
The South African Health Products Regulatory Authority (SAHPRA) has approved the Phase 2/3 study of once-daily orally-administered RHB-107 (upamostat) for patients with symptomatic COVID-19 who do not require hospital care Number of U.S. sites for the study has also been expanded RHB-107, a nov...
2021-09-13 19:00
6867
FUJIFILM Diosynth Biotechnologies and NeuExcell Therapeutics enter manufacturing agreement to rapidly advance NXL-001, a potential neuro-regeneration gene therapy to treat ischemic cortical stroke
STATE COLLEGE, Pa., Sept. 13, 2021 /PRNewswire/ -- * FUJIFILM Diosynth Biotechnologies (FDB) will provide essential drug substance and drug product manufacturing, under accelerated timelines, for NeuExcell's first-in-human clinical studies * Drug substance manufacturing will be carried out in...
2021-09-13 18:00
2345
Hummingbird Bioscience Announces US FDA Clearance of IND for First-in-Human Phase 1 Trial of HMBD-002 in Patients with Advanced Solid Tumors
HOUSTON and SINGAPORE, Sept. 13, 2021 /PRNewswire/ -- Hummingbird Bioscience, an innovative clinical-stage biotech company focused on developing precision therapies against hard-to-drug targets, today announced that the U.S. Food and Drug Administration (FDA) has approved the initiation of a Phas...
2021-09-13 17:00
2148
Week's Top Stories
Most Reposted
Digital Identity Co. Modernizes Thailand Immigration Bureau Services with AWS
[Picked up by 314 media titles]
2026-05-28 15:06Agoda and Philippines Department of Tourism announce strategic partnership to promote and elevate tourism
[Picked up by 290 media titles]
2026-05-27 09:16
Asian Society of Cardiovascular Imaging and Philips sign MOU to strengthen imaging capabilities across Asia Pacific
[Picked up by 289 media titles]
2026-05-28 17:34
ASEAN Business Advisory Council (ASEAN-BAC) and AVPN Establish Regional Platform to Strengthen Corporate Social Investment and Cross-Sector Collaboration Across Southeast Asia
[Picked up by 288 media titles]
2026-05-28 10:06Patong Stay & Dine Package at Courtyard by Marriott Phuket, Patong Beach Resort
[Picked up by 283 media titles]
2026-05-28 14:10
Most Read
Agoda and Philippines Department of Tourism announce strategic partnership to promote and elevate tourism
2026-05-27 09:16
6814
Creality Charts Next Decade as AI-Powered Consumer 3D Creative Platform, Hong Kong listing anchors the company's full-stack ecosystem shift
2026-05-30 11:58
6654
NYSE Content Update: Hinge Health Shares Up 72% One Year from its IPO
2026-05-28 21:14
6561
